Back to Search
Start Over
Induction of antigen-specific tolerance by nanobody-antigen adducts that target class-II major histocompatibility complexes.
- Source :
-
Nature biomedical engineering [Nat Biomed Eng] 2021 Nov; Vol. 5 (11), pp. 1389-1401. Date of Electronic Publication: 2021 Jun 14. - Publication Year :
- 2021
-
Abstract
- The association of autoimmune diseases with particular allellic products of the class-II major histocompatibility complex (MHCII) region implicates the presentation of the offending self-antigens to T cells. Because antigen-presenting cells are tolerogenic when they encounter an antigen under non-inflammatory conditions, the manipulation of antigen presentation may induce antigen-specific tolerance. Here, we show that, in mouse models of experimental autoimmune encephalomyelitis, type 1 diabetes and rheumatoid arthritis, the systemic administration of a single dose of nanobodies that recognize MHCII molecules and conjugated to the relevant self-antigen under non-inflammatory conditions confers long-lasting protection against these diseases. Moreover, co-administration of a nanobody-antigen adduct and the glucocorticoid dexamethasone, conjugated to the nanobody via a cleavable linker, halted the progression of established experimental autoimmune encephalomyelitis in symptomatic mice and alleviated their symptoms. This approach may represent a means of treating autoimmune conditions.<br /> (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)
Details
- Language :
- English
- ISSN :
- 2157-846X
- Volume :
- 5
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Nature biomedical engineering
- Publication Type :
- Academic Journal
- Accession number :
- 34127819
- Full Text :
- https://doi.org/10.1038/s41551-021-00738-5